This financing builds on IFC’s anchor role in Hikma’s $500 million, five-year bond issuance, which included a $50 million subscription from IFC ...

Hikma Pharmaceuticals PLC closed 16.86% below its 52-week high of £23.60, which the company reached on February 13th.

Hikma Pharmaceuticals USA (OTCPK:HKMPF) plans to invest $1 billion through 2030 to boost its U.S. manufacturing and R&D. Under its "America Leans on Hikma" initiative, investment aims to enhance the ...

The financing will be directed toward scaling Hikma’s operations across key MENA markets and addressing high unmet healthcare needs in the region.

This financing builds on IFC’s anchor role in Hikma’s $500 million, five-year bond issuance, which included a $50 million ...

America Leans on Hikma represents the company’s latest efforts to increase the volume of essential medicines it develops and ...

Hikma said Tyzavan is the only FDA-approved vancomycin product commercially available for all patients that is available at room temperature and requires no compounding, thawing, activation or ...

Eight drugmakers agreed to put legal claims stemming from their roles in the U.S. | Viatris, Hikma, Amneal, Apotex, Indivior, ...

Key Highlights • Hikma inks a $250 million loan agreement with the International Finance Corporation (IFC). • The funds will support local pharmaceutical production in North Africa and the Middle East ...

Hikma Pharmaceuticals will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities.

Hikma Pharmaceuticals. Hikma Pharmaceuticals USA Announces $1 Billion of New US Investment to Further Expand its Domestic Manufacturing and Development of Essential Generic Medicines. Press Release.

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines By Hikma Pharmaceuticals USA Inc.